Story
Aptevo Therapeutics Stock Falls Despite Positive AML Drug Trial Data
Aptevo Therapeutics (NASDAQ: APVO) shares plunged in pre-market trading despite the company reporting positive clinical trial data, as investors focused on a significant stock dilution overhang and engaged in a classic "sell-the-news" reaction.
Positive Data, Negative Reaction
Aptevo announced encouraging results from its Phase 1b/2 trial for its mipletamig triplet therapy. The company reported a 93% clinical benefit rate in evaluable frontline acute myeloid leukemia (AML) patients with TP53 mutations, a highly treatment-resistant form of the disease.
Key results from the patient subset included:
- A 79% remission rate, with 11 of 14 evaluable patients achieving complete remission or complete remission with incomplete hematologic recovery.
- This rate substantially surpasses a published historical benchmark of 41% for this patient group.
Despite the positive clinical update, the stock fell 17.3% to $2.15 in pre-open trading, according to Investing.com.
AdDilution Overhang Weighs on Shares
The sharp decline appears primarily driven by concerns over substantial shareholder dilution. An August 2026 warrant inducement and a private investment in public equity (PIPE) financing created the potential for more than 6.4 million new shares to be registered for resale.
This figure represents a significant overhang for the market, dwarfing the roughly 1.8 million shares of common stock the company had outstanding as of late August. The prospect of such a large number of new shares entering the market is creating substantial selling pressure.
Broader Context
A tepid broader market provided little support, with the S&P 500 and Nasdaq Composite showing only modest gains. The stock's technical posture also remains bearish, with shares having fallen dramatically from a 52-week high of $48.78 and trading near the 52-week low of $2.30. The convergence of profit-taking on anticipated news and the looming dilution risk is currently outweighing the company's scientific progress.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.
Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.
Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.
DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.